Nottingham University Hospitals appoints Genmed as managed service partner

By Sophie Chapman
The UK managed service provider, Genmed, has been selected by Nottingham University Hospitals as a vendor-neutral managed service provider in order to w...

The UK managed service provider, Genmed, has been selected by Nottingham University Hospitals as a vendor-neutral managed service provider in order to work with its point of care team (POCT).

The appointment is initially contracted for 5 years, but there is a potential for extension.

It will be Genmed’s responsibility to manage the relationship with third-party providers to ensure quality service delivery at good prices.

Initially, the company is required to provide blood glucose and ketone meters for use at point of care, as well as an IT solution that connects the monitoring equipment and associated consumables.

SEE ALSO:

In 2016, the Trust used 825,400 glucose strips and 20,750 ketone strips.

It is expected that additional point of care products are to be added to the contract at some point, including cholesterol, urine, INR, and haemoglobin meters, as well as pregnancy and HIV tests, and blood gas analysers.

It is estimated that 24 hours a day, there are 5,000 to 6,000 nurses and 2,000 to 3,000 doctors who use point of care systems.

“Following a formal tendering process, Genmed was awarded the POCT contract. They have an established track record of working with NHS Trusts based on a decade of experience,” stated Tony Stanyard, Head of Procurement at Notting University Hospital.”

“This gave us the confidence that they could really deliver improvement in our point of care testing services yet save money at the same time.”

Share

Featured Articles

UnitedHealth CEO Admits Hack hit Third of US Citizens' Data

UnitedHealth Group CEO Andrew Witty tells stunned US congressional hearing Change Healthcare cyberattack affects third of the US population

Why Sanofi Leads the way on Healthcare Sustainability

How French multinational Sanofi is ensuring delivery of essential medical supplies while being ESG-compliant

Philips Q1 Results hit by $1.1bn Respironics Settlement

As Royal Philips reports Q1 2024 results we profile the Netherlands-based healthcare technology company, who made the switch from consumer electronics

Vaccine Breakthrough on Antibiotics Resistant Diseases

Medical Devices & Pharma

Oracle Fusion Cloud Update Boost for Patients

Technology & AI

WHO Tightens air Quality Guidelines as Pollution Kills 7mn

Sustainability